Review Article

Liposomal Medicine: Drug Delivery Systems from Concept to Clinical operation

Sejal Dhotre*, Shrikrishna Baokar, Rajendra Patil
Delonix Society's Baramati College of Pharmacy, Barhanpur, Baramati, Dist Pune, Maharashtra, India 413102.
***Corresponding author's E-mail:** sejaldhotre1103@gmail.com

Received: 06-04-2025; **Revised:** 23-06-2025; **Accepted:** 10-07-2025; **Published online:** 15-07-2025.

ABSTRACT

Liposomal medicine delivery systems represent a groundbreaking advancement in pharmaceutical lores, offering an effective platform for the targeted delivery of remedial agents. By recapitulating medicines within lipid bilayers, liposomes enhance medicine solubility, reduce systemic toxin, and protract rotation time. This review provides a comprehensive overview of liposome technology, from its abstract origins to current clinical operations. It discusses the bracket, medication styles, medicine lading strategies, and characterization ways, alongside real- world exemplifications of FDA- approved liposomal medicines. Likewise, the review explores current challenges, implicit results, and unborn perspectives in optimizing liposome- grounded delivery for perfection drug. Liposomal medicine delivery systems have come a foundation in the development of advanced pharmaceutical phrasings, particularly for clinical use. By recapitulating remedial agents within biocompatible lipid bilayers, liposomes offer bettered medicine solubility, enhanced bioavailability, and the capability to target specific apkins or cells. These features contribute to reduced systemic toxin and bettered remedial issues. Clinically, liposomal phrasings have been approved for the treatment of colourful conditions, including cancer, fungal infections, and viral conditions. Notable exemplifications include liposomal doxorubicin for cancer remedy and liposomal amphotericin B for systemic fungal infections. Inventions similar as PEGylation and ligand targeting have further meliorated liposomal systems, enhancing rotation time and particularity. As exploration continues to evolve, liposomes are anticipated to play an increasingly important part in delivering complex rectifiers, including inheritable accoutrements and immunotherapies, across a wide range of clinical settings.

Keywords: Liposome, biocompatible, targeted delivery, enhanced bioavailability, cancer.

INTRODUCTION

The delivery of remedial agents with optimal efficacy and minimum side goods has been a longstanding challenge in the field of drug delivery. Traditional medicine delivery styles frequently suffer from poor solubility, rapid-fire metabolism, and lack of selectivity, leading to sour remedial issues. Liposomes, first discovered in the 1960s, have surfaced as a feasible result to these limitations. Composed of one or further phospholipid bilayers girding an waterless core, liposomes can synopsize both hydrophilic and lipophilic medicines, offering a protean system for medicine delivery.



Figure 1: Structure of liposome

The adding interest in nanotechnology and targeted medicine delivery has deposited liposomes at the van of pharmaceutical exploration. With several liposomal phrasings now approved by nonsupervisory bodies similar as the FDA and EMA, their clinical applicability continues to grow. This review explores the crucial aspects of liposomal medicine delivery systems, pressing their structural design, functional advantages, medication ways, and remedial eventuality.

The advancement of medicine delivery technologies has significantly impacted the effectiveness and safety of remedial interventions. Among these technologies, liposomal medicine delivery systems have surfaced as one of the most promising approaches in clinical practice. Liposomes are globular vesicles composed of one or further phospholipid bilayers(Figure 1), able of recapitulating both hydrophilic and hydrophobic medicines.

Their structural flexibility and biocompatibility make them ideal carriers for a wide range of pharmaceutical agents. In clinical settings, liposomal phrasings have been developed to enhance medicine stability, ameliorate pharmacokinetics, and reduce systemic toxin. This has led to the blessing of several liposomal medicines for conditions similar as cancer, fungal infections, and viral conditions. Inventions in liposome engineering, including face revision and targeted delivery, have further expanded their eventuality in perfection drug. This preface highlights the significance of liposomal medicine delivery systems in clinical operations and their ongoing elaboration in ultramodern rectifiers.

2. Literal Background of Liposomes[3,4]

The development of liposomes can be traced back to the early 1960s, when British haematologist Alec Bangham first described lipid bilayer structures while studying phospholipids in water. Originally observed under electron microscopy, these globular vesicles displayed parcels analogous to natural membranes, sparking interest in their eventuality as medicine carriers. Over the decades, advances in lipid chemistry, expression wisdom, and characterization tools have propelled liposomes from experimental curiosity to clinical reality.

In the 1970s and 1980s, exploration concentrated on perfecting liposome stability and targeting capabilities, leading to the development of covert liposomes and ligand-targeted vesicles. By the 1990s, liposomes had entered clinical practice, with Doxil(liposomal doxorubicin) getting the first FDA- approved liposomal medicine. Since also, liposomes have been used in treating cancer, fungal infections, and viral conditions, marking their significance in ultramodern rectifiers.

3. Bracket and Types of Liposomes[5,6]

Liposomes can be classified grounded on size, number of bilayers, face charge, and composition. Common groups include

- Small Unilamellar Vesicles (SUVs) 20 – 100 nm in periphery, containing a single lipid bilayer.

- Large Unilamellar Vesicles (LUVs) 100 – 1000 nm, single bilayer but larger volume for medicine lading.

- Multilamellar Vesicles (MLVs) Multiple concentric bilayers, suggesting an onion- suchlike structure. Stealth Liposomes carpeted with polyethylene glycol (cut) to shirk the vulnerable system and protract rotation.

-Cationic and Anionic Liposomes Designed to alter the face charge for specific relations with cells or motes.



Figure 2: Classification of liposomes

Each type has distinct advantages and is chosen grounded on the asked medicine delivery operation, pharmacokinetics, and target towel conditions.

4. Styles of Liposome Preparation[7,8]

Liposomes can be prepared using colourful ways depending on the asked size, lamellarity, and operation.

The most common styles include

1. Thin Film Hydration Method This is one of the oldest and most extensively used styles. Lipids are dissolved in an organic detergent and faded to form a thin lipid film, which is also doused with a waterless buffer to form liposomes. The performing suspense may contain MLVs that bear further processing.

2. Rear Phase Evaporation system Lipids are emulsified in a water- in- oil painting conflation, also the detergent is removed under reduced pressure. This system yields LUVs and offers high encapsulation effectiveness.

3. Ethanol Injection and soap junking these styles involve edging in lipid results into waterless phases, leading to robotic vesicle conformation. Suitable for forming SUVs but bear careful solvent junking.

4. Microfluidic ways Advanced, scalable styles involving the controlled mixing of lipids and waterless phases within micro channels. These ways give better reproducibility and control over liposome size.

5. Medicine lading Strategies[9,10]

Liposomes can be loaded with medicines using two main approaches

1. Passive loading this system involves recapitulating the medicine during liposome conformation. Hydrophilic medicines are entangled in the waterless core, while lipophilic medicines are bedded in the lipid bilayer. Passive lading is simple but frequently suffers from low encapsulation effectiveness.

2. Active lading (Remote lading) this fashion exploits Trans membrane ion slants (e.g., ammonium sulphate or pH grade) to drive the accumulation of medicines into preformed liposomes. It allows high medicine lading effectiveness and bettered stability, especially for weakly introductory composites like doxorubicin. Medicine lading strategy affects release profile, bioavailability, and remedial performance. Thus, it must be named grounded on the physicochemical parcels of the medicine and the intended clinical operation.

6. Characterization of Liposomes[11,12]

Characterization of liposomes is pivotal to ensure reproducibility, stability, and performance of the medicine delivery system. Crucial parameters include

1. Size and Size Distribution Determined using dynamic light scattering (DLS) or nanoparticle shadowing analysis. The flyspeck size influences rotation time, cellular uptake, and bio distribution.

2. Zeta Implicit Indicates face charge, which affects colloidal stability and commerce with natural membranes.

3. Encapsulation Efficiency (EE) Measured to estimate the quantum of medicine successfully entangled in the liposomes. Ways like ultracentrifugation, dialysis, or chromatography are used.

4. Morphology Transmission electron microscopy (TEM) and cryo- electron microscopy help fantasize liposome shape, lamellarity, and integrity.

5. In Vitro Release Profile medicine release kinetics can be studied using dialysis styles to assess sustained or burst release.

7. Mechanisms of medicine Release[13,14]

Liposomes release their cargo via colourful mechanisms depending on lipid composition, size, and environmental factors. The primary mechanisms include-

- Diffusion Passive release through the lipid bilayer into the girding medium.

- Membrane Fusion with target cell membranes leading to direct medicine transfer.

- Endocytosis- Liposomes are internalized by cells, followed by release in the cytoplasm.

- Environmental Alarms pH-sensitive or temperature-sensitive liposomes release medicines in response to changes in the original terrain, enhancing point-specific delivery.

Understanding these release mechanisms is essential for designing liposomes acclimatized for controlled and targeted delivery.

8. Operations of Liposomal Drug Delivery[15-17]

Liposomal medicine delivery systems have set up wide-ranging operations in drug delivery due to their capability to ameliorate the pharmacokinetics and biodistribution of colourful remedial agents

- Cancer Therapy Liposomes are used to deliver chemotherapeutics similar as doxorubicin and paclitaxel, reducing off- target toxin and enhancing excrescence accumulation via the enhanced permeability and retention (EPR) effect.

- Antimicrobial Delivery Liposomal amphotericin B has revolutionized the treatment of systemic fungal infections by reducing nephrotoxicity.

- Vaccines Liposomes are used as adjuvants in vaccine delivery, perfecting antigen donation and vulnerable response.

- For Gene Therapy, Cationic liposomes grease the delivery of inheritable material similar as plasmids and siRNA into target cells.

- Dermatology and Cosmetics- Liposomal phrasings enhance skin penetration and stability of active composites.

These operations demonstrate the versatility and clinical value of liposomal phrasings in both systemic and localized delivery.

9. Advantages and Limitations[18-21]

Advantages

- Biocompatible and biodegradable.

-Capable of carrying both hydrophilic and hydrophobic medicines.

- Reduced medicine toxicity and enhanced remedial indicator.

- Possibility of controlled and targeted medicine release.

Limitations

-High production cost and scale- up challenges.

-Physical and chemical instability during storehouse.

-Limited shelf- life and threat of unseasonable medicine leakage.

-Complex nonsupervisory pathways.

Despite these limitations, advancements in expression wisdom are continuously perfecting the stability, efficacy, and affordability of liposomal medicine delivery systems.

10. Clinical operations and FDA- Approved Products[22-24]

These products punctuate the success and growing significance of liposomes in ultramodern remedial rules.

Table 1: Various pharmaceutical applications of liposomes along with examples

Pharmaceutical applications	Examples
Enhancing solubilization of entrapped drug	Minoxidil, Amphotericin B
Accumulation of drug in stratum corneum	Lidocaine, Prostaglandins
Drug molecule protection	Interleukins, Cytosine arabinoside
Achieving sustained release	Antineoplastic drugs (eg:5-Flurouracil), Antitubercular drugs (eg: Isoniazid and Rifampicin), Hormones, Corticosteroids (eg: Hydrocortisone)
Avoiding toxicity	Amphotericin B (nephrotoxicity reduction), Doxorubicin (cardiotoxicity reduction)
Enhanced skin penetration	Ketoconazole
Targeted drug delivery	Immunomodulators (eg: Paclitaxel loaded polyethylene glycolated immunoliposome), Antimalarials, Vaccines.
Enhancement of drug half life	Antifungal drugs (eg: Ketoconazole)

Several liposomal phrasings have entered nonsupervisory blessing and are extensively used in clinical settings

- Doxil (Doxorubicin HCl Liposome Injection) The first FDA-approved liposomal anticancer medicine used for ovarian cancer, Kaposi's sarcoma, and multiple myeloma.

- AmBisome (Liposomal Amphotericin B) Used to treat systemic fungal infections with significantly reduced nephrotoxicity.

- DepoCyt (Liposomal Cytarabine) Administered for lymphomatous meningitis to give sustained medicine release in cerebrospinal fluid.

- Vyxeos (Liposomal Daunorubicin and Cytarabine) Approved for high- threat acute myeloid leukemia (AML), offering bettered survival benefits.

11. Current Challenges and Future Perspectives[25]

Despite their clinical successes, liposomal systems face several challenges-

- Scalability and cost of product remain significant hurdles for wide marketable relinquishment.

- Stability issues similar as aggregation, oxidation, or medicine leakage during storehouse reduce shelf- life. SS

-natural walls, including rapid-fire concurrence by the mononuclear phagocyte system(MPS), can limit remedial efficacy.

Unborn directions include the development of smart liposomes responsive to specific natural stimulants, face-modified liposomes for better targeting, and substantiated Nano medicine approaches. Integration with artificial intelligence (AI) and machine literacy could also optimize liposome design, enhancing medicine delivery issues.

CONCLUSION

Liposomal medicine delivery systems have converted the pharmaceutical geography by enabling safer and further effective delivery of a wide range of remedial agents. Their capability to synopsize both hydrophilic and hydrophobic medicines, reduce systemic toxin, and give point-specific delivery has led to multitudinous clinical successes. Ongoing exploration continues to ameliorate liposome phrasings, offering new possibilities in perfection drug and Nano therapeutics. As technological advancements address current limitations, liposomes are anticipated to play an increasingly vital part in the future of medicine delivery.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews. 2013 Jan 1;65(1):36-48. DOI:https://doi.org/10.1016/j.addr.2012.09.037 ;PMID: 23036225.

2. Barenholz YC. Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of controlled release. 2012 Jun 10;160(2):117-34.DOI:https://doi.org/10.1016/j.jconrel.2012.03.020 ; PMID:22484195.

3. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends in biotechnology. 1995 Dec 1;13(12):527-37.DOI:https://doi.org/10.1016/s0167-7799(00)89017-4 ;PMID:8595139.

4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005 Feb 1;4(2):145-60.DOI:https://doi.org/10.1038/nrd1632 ;PMID:15688077.

5. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of molecular biology. 1965 Aug 1; 13(1): 238IN27. DOI:https://doi.org/10.1016/s0022-2836(65)80093-6 ;PMID:5855039.

6. Laura Immordino M, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine. 2006 Sep 15;1(3):297-315.DOI:https://pmc.ncbi.nlm.nih.gov/articles/PMC2426795/ ;PMID:17717971.

7. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Frontiers in pharmacology. 2015 Dec 1 ;6: 286.

DOI:https://doi.org/10.3389/fphar.2015.00286 ;PMID:26648870.

8. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale research letters. 2013 Dec;8:1-9.DOI:https://doi.org/10.1186/1556-276x-8-102 ;PMID:23432972.

9. Silverman JA, Deitcher SR. Marqibo®(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer chemotherapy and pharmacology. 2013 Mar;71(3):555-64.DOI:https://doi.org/10.1007/s00280-012-2042-4 ;PMID:23212117.

10. Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug delivery. 2016 Nov 21;23(9):3319-29.DOI:https://doi.org/10.1080/10717544.2016.1177136 ;PMID:27145899.

11. Bozzuto G, Molinari A. Liposomes as nanomedical devices. International journal of nanomedicine. 2015 Feb 2:975-99.DOI:https://doi.org/10.2147/ijn.s68861 ;PMID:25678787.

12. Allen TM. Liposomes: opportunities in drug delivery. Drugs. 1997 Oct;54(Suppl 4):8-14.DOI:https://doi.org/10.2165/00003495-199700544-00004 ;PMID:9361956.

13. Lasic DD. Liposomes in gene delivery. CRC press; 2019 Jul 23.DOI:https://doi.org/10.1201/9780138748807.

14. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. International journal of pharmaceutics. 1997 Aug 26;154(2):123-40.DOI:https://doi.org/10.1016/S0378-5173(97)00135-X.

15. Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artificial cells, nanomedicine, and biotechnology. 2016 Jan 2;44(1):381-91.DOI:https://doi.org/10.3109/21691401.2014.953633 ;PMID:25222036.

16. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in lipid research. 2003 Nov 1;42(6):463-78. DOI:https://doi.org/10.1016/s0163-7827(03)00033-x ;PMID:14559067.

17. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1991 Sep 30;1068(2):133-41. DOI:https://doi.org/10.1016/0005-2736(91)90201-i; PMID:1911826.

18. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1991 Jul 1;1066(1):29-36. DOI:https://doi.org/10.1016/0005-2736(91)90246-5 ;PMID:2065067.

19. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chemical reviews. 2015 Oct 14;115(19):10938-66. DOI:https://doi.org/10.1021/acs.chemrev.5b00046 ;PMID: 26010257

20. Miere F, Fritea L, Cavalu S, Vicaș SI. Formulation, Characterization, and Advantages of Using Liposomes in Multiple Therapies. Pharmacophore. 2020;11(3-2020):1-2. DOI:https://pharmacophorejournal.com/WFzrTpR.

21. Fielding RM. Liposomal drug delivery: advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clinical Pharmacokinetics. 1991 Sep;21(3):155-64. DOI:https://doi.org/10.2165/00003088-199121030-00001 ; PMID:1764868.

22. Lao J, Madani J, Puértolas T, Álvarez M, Hernández A, Pazo-Cid R, Artal Á, Antón Torres A. Liposomal doxorubicin in the treatment of breast cancer patients: a review. Journal of drug delivery. 2013;2013(1):456409. DOI: https://doi.org/10.1155/2013/456409 ;PMID:23634302.

23. Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016 Mar ; 76:485-500. DOI:https://doi.org/10.1007/s40265-016-0538-7 ;PMID:26818726.

24. Burdușel AC, Andronescu E. Lipid nanoparticles and liposomes for bone diseases treatment. Biomedicines. 2022 Dec 7;10(12):3158. DOI:https://doi.org/10.3390/biomedicines10123158 ;PMID:36551914.

25. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. Journal of pharmaceutical sciences. 2001 Jun 1;90(6):667-80. DOI:https://doi.org/10.1002/jps.1023 ;PMID:11357170.